EGFR and pneumonitis: In the TKI setting, symptomatic grade 3–4 pneumonitis occurred in approximately 6–7% of patients receiving thoracic RT with first-generation EGFR-TKIs in SINDAS, and in 5.1% of those treated with concurrent thoracic RT plus osimertinib in Sun’s phase III trial (any-grade incidence, 32.2% vs. 1.7% with osimertinib alone) [29,30].